WADA comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-08. Numbers and descriptions here follow the published literature rather than marketing material.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
=== Medications === Some medications, such as glucocorticoids, cannabinoids, and progestins were initially used in treating cachexia and aim to increase appetite. Progestins showed promise initially, but they do not stop muscle wasting and may cause fluid retention, fat gain, and other side effects. Ghrelin agonists, such as anamorelin are commonly used in cancer treatment to boost appetite, increase weight, and increase muscle mass. However, its use and effectiveness in cachexia is not well studied. Selective androgen receptor modulators (SARMs) such as enobosarm show promise in increasing physical performance and muscle mass, but more studies are needed to confirm their effectiveness in cachexia. The use of anti-inflammatory medications have been investigated. Thalidomide, an anti-inflammatory agent, has shown promise in preventing weight loss, but the use of this medication in cachexia is not widely accepted. However, other TNF inhibitors have not shown the same promising results. NSAIDs such as celecoxib and ibuprofen showed some early benefits, but side effects (renal injury, GI bleeding) limit their use. Anti-nausea drugs such as 5-HT3 antagonists are also commonly used if nausea is a prominent symptom. Anabolic steroids like oxandrolone may help but are only recommended for short term use due to side effects including liver toxicity.
The first wave of modern Jewish migration to Ottoman-ruled Palestine, known as the First Aliyah, began in 1881, as Jews fled pogroms in Eastern Europe. Although the Zionist movement already existed in practice, Austro-Hungarian journalist Theodor Herzl is credited with founding political Zionism, a movement that sought to establish a Jewish state in Palestine, thus offering a solution to the so-called Jewish question of the European states, in conformity with the goals and achievements of other national projects of the time. In 1896, Theodor Herzl set out his vision of a Jewish state and homeland for the Jewish people in his book Der Judenstaat (The Jewish State). The following year he presided over the First Zionist Congress in Basel, at which the Zionist Organization was founded. The draft of the objective of the modern Zionist movement submitted to the First Zionist Congress of the Zionist Organization in 1897 read: "Zionism seeks to establish a home for the Jewish people in Palestine secured by law." One delegate sought to replace "by law" with "by international law", which was opposed by others. A compromise formula was adopted, which came to be known as the Basel Program, and read:
==== Alkaline phosphatase ==== Alkaline phosphatase from E. coli can be purified using a DEAE-Cellulose matrix. A. phosphatase has a slight negative charge, allowing it to weakly bind to the positively charged amine groups in the matrix. The enzyme can then be eluted out by adding buffer with higher salt concentrations.
It has also been shown that expression can be improved by fusion to maltose binding protein (MBP) which acts a solubility-enhancing partner. A more recent solution is offered by the Numacut variant, which combines multiple stabilizing and solubility-enhancing mutations. Numacut is expressed in high yields in E. coli, exhibits significantly improved solubility, and remains stable across a broad range of pH, salt concentrations, and buffer additives. In contrast to the wild-type enzyme, it can also be lyophilized and stored at room temperature, enhancing its applicability in industrial and pharmaceutical settings. TEV protease has been reported to show a 10-fold loss of activity at 4 °C. TEV protease shows loss of activity at temperatures above 34 °C. The original TEV protease required the presence of reducing agent for high activity, which could interfere with the function of proteins containing disulfide bonds. After incorporation of various mutations, later "superTEV protease" versions are highly active in the presence or absence of reducing agent. The molecular weight of this enzyme varies between 25 and 27 kDa depending on the specific construct used.
==== Type I antithrombin deficiency ==== Type I antithrombin deficiency is characterized by a decrease in both antithrombin activity and antithrombin concentration in the blood of affected individuals. Type I deficiency was originally further divided into two subgroups, Ia and Ib, based upon heparin affinity. The antithrombin of subgroup Ia individuals showed a normal affinity for heparin while the antithrombin of subgroup Ib individuals showed a reduced affinity for heparin. Subsequent functional analysis of a group of 1b cases found them not only to have reduced heparin affinity but multiple or 'pleiotropic' abnormalities affecting the reactive site, the heparin binding site and antithrombin blood concentration. In a revised system of classification adopted by the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, type Ib cases are now designated as type II PE, Pleiotropic effect. Most cases of type I deficiency are due to point mutations, deletions or minor insertions within the SERPINC1 gene. These genetic mutations result in type I deficiency through a variety of mechanisms:
Sources: en.wikipedia.org
=== Casting === Brec Bassinger was cast as Courtney Whitmore / Stargirl in September 2018. Johns called the casting of Stargirl a difficult process, auditioning hundreds of actresses for the role. On why Bassinger was perfect for the role, Johns said: "Immediately... I knew she was Courtney. She has the humor, she has the enthusiasm, the energy, the innate optimism, and Brec really embodies who Stargirl is". The following roles were cast in November: Anjelika Washington as Beth Chapel / Doctor Mid-Nite, Yvette Monreal as Yolanda Montez / Wildcat, and Christopher James Baker as Henry King / Brainwave. In January 2019, Luke Wilson was cast as Pat Dugan / S.T.R.I.P.E. Amy Smart joined the cast as Barbara Whitmore in February, along with Neil Jackson as Jordan Mahkent / Icicle, Trae Romano as Mike Dugan, Hunter Sansone as Cameron, and Cameron Gellman as Rick Tyler / Hourman. Also Jake Austin Walker was cast as Henry King Jr. and Meg DeLacy cast as Cindy Burman. The following members of the Justice Society of America were cast in December 2018: Joel McHale as Sylvester Pemberton / Starman, Lou Ferrigno Jr. as Rex Tyler / Hourman, Brian Stapf as Ted Grant / Wildcat, and Henry Thomas as Charles McNider / Doctor Mid-Nite. As well, Joy Osmanski was cast as Paula Brooks / Tigress, Neil Hopkins was cast as Lawrence "Crusher" Crock / Sportsmaster, and Nelson Lee was cast as Dr. Ito / Dragon King, members of the Injustice Society. In April 2019, Hina Khan was cast as Anaya Bowin.
On July 3, 2023, a complaint was filed stating the Boston Market in Danbury, Connecticut, owed in excess of $61,000 in unpaid rent and connected charges. A ruling in the landlord's favor on July 28, 2023, led to an eviction. On July 25, 2023, US Foods sued Boston Market for $11.3 million, accusing the company of owing them over $10 million for food distributed over several prior years. On August 14, 2023, the New Jersey Department of Labor and Workforce Development issued a stop-work order at 27 of the 31 Boston Market stores in New Jersey over multiple violations of workers rights, including owed backpay of up to $607,471 to up to 314 employees. An investigation on the matter began in November 2022 when an employee in Mercer County filed a complaint. The affected employees have since been reimbursed for their lost wages, and the stores were allowed to re-open a month later. In September 2023, investigative journalists of Restaurant Business Magazine revealed Pandya had over 200 lawsuits against him related to unpaid wages of employees, unpaid suppliers, and other violations related to his restaurants. The report described Pandya's ownership of Boston Market as "chaotic". In November 2023, the company failed to pay workers in Massachusetts. On November 14, 2023, all Detroit-area Boston Market locations were permanently shuttered and were handed eviction notices due to unpaid rent.
In line with its role as a first line defense system, SP is released when toxicants or poisons come into contact with a range of receptors on cellular elements in the chemoreceptor trigger zone, located in the floor of the fourth ventricle of the brain (area postrema). Presumably, SP is released in or around the nucleus of the solitary tract upon integrated activity of dopamine, serotonin, opioid, and/or acetylcholine receptor signaling. NK1Rs are stimulated. In turn, a fairly complex reflex is triggered involving cranial nerves responsible for respiration, retroperistalsis, and general autonomic discharge. The actions of aprepitant are said to be entirely central, thus requiring passage of the drug into the central nervous system. However, given that NK1Rs are unprotected by a blood brain barrier in the area postrema just adjacent to neuronal structures in the medulla, and the activity of sendide (the peptide based NK1RA) against cisplatin-induced emesis in the ferret, it is likely that some peripheral exposure contributes to antiemetic effects, even if through vagal terminals in the clinical setting.
==== Imaging ==== Ultrasound of the thyroid may be used to reveal whether structures are solid or filled with fluid, helping to differentiate between nodules and goitres and cysts. It may also help differentiate between malignant and benign lesions. When further imaging is required, a radiolabelled iodine-123 or technetium-99 uptake scan may take place. This can determine the size and shape of lesions, reveal whether nodules or goitres are metabolically active, and reveal and monitor sites of thyroid disease or cancer deposits outside the thyroid. A fine needle aspiration of a sample of thyroid tissue may be taken in order to evaluate a lesion seen on ultrasound which is then sent for histopathology and cytology. Computed tomography of the thyroid plays an important role in the evaluation of thyroid cancer. CT scans often incidentally find thyroid abnormalities, and thereby practically becomes the first investigation modality.
The World Organization of the Scout Movement (WOSM ), branded as World Scouting since 2024, is the largest and, after the Order of World Scouts (formed in 1911), is the second-oldest international organisation in the Scout Movement, having been established in 1922 as The International Conference of the Boy Scout Movement. It has 176 members. These members are national scout organisations that founded WOSM or have subsequently been recognised by WOSM, which in 2025 collectively have around 51.4 million participants (up from 43 million in 2022), and a reach of 60 million young people. Its operational headquarters is in Kuala Lumpur, Malaysia, although it is legally based in Geneva, Switzerland. WOSM's stated mission is "to contribute to the education of young people, through a value system based on the Scout Promise and Scout Law, to help build a better world where people are self-fulfilled as individuals and play a constructive role in society". WOSM operates through conferences of its member organisation representatives, its committee and its full-time bureau, structured into regions. It is associated with three World Scout Centres. A World Scout Jamboree is held approximately every four years under its auspices and it organizes World Scout Moots for 17- to 26-year-olds and previously organised World Scout Indabas, a gathering for Scout leaders. The World Scout Foundation is a separately governed fund, supported by donations, for the development of WOSM associated programmes. WOSM is the counterpart of the World Association of Girl Guides and Girl Scouts (WAGGGS).
Sources: en.wikipedia.org
=== Burnout prevention and balancing life === After his personal experience with burnout at the peak of his medical career, Maroon developed a strong interest in burnout prevention and living a more balanced life. He conducted extensive research into burnout, burnout prevention, and what constitutes a healthy, balanced, and successful life outside of a professional career. Maroon has given keynote presentations on this subject matter at national and international conferences. In 2017, he published the book Square One: A Simple Guide to a Balanced Life. In 2025, he was the keynote speaker at Focus Forward 2025 for the state of West Virginia, where he spoke on the topic "How to Die Young as Late as Possible." He has also participated in numerous interviews and seminars promoting healthy living and longevity.
=== Synthesis === 3-CMC is commonly synthesized starting from 3-chloropropiophenone. 3-chloropropiophenone is subjected to alpha halogenation using bromine. Subsequently, methylamine acts as a nucleophile and displaces bromide in a nucleophilic substitution to form a racemic product. Cathinones are usually unstable as a freebase, so the product is often treated with HCl or HBr to form a hydrochloride or hydrobromide salt, respectively.
== Awards and honours == 2007 Elected to the British Mass Spectrometry Society 2018 Elected Chair of the Management Advisory Panel for the EPSRC National Mass Spectrometry Facility 2022 Royal Society of Chemistry Analytical Division Theophilus Redwood Award
In April 2020, Lilly announced they were investigating the use of baricitinib for treating people with COVID-19. The drug's anti-inflammatory activity was expected to act on the inflammatory cascade associated with COVID-19. In April and June 2020, the first two studies of baricitinib prescribed for hospitalized people with COVID-19 were published online. Then in November 2020, published research showed baricitinib was beneficial in treating people with COVID-19. According to the paper "mechanistic actions of a Janus kinase-1/2 inhibitor targeting viral entry, replication and the cytokine storm, and is associated with beneficial outcomes including in severely ill elderly people". In a clinical trial of hospitalized people with COVID-19, baricitinib, in combination with remdesivir, was shown to reduce time to recovery within 29 days after initiating treatment compared to participants who received a placebo with remdesivir. The data supporting the US Food and Drug Administration (FDA) emergency use authorization (EUA) for baricitinib combined with remdesivir was based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the US National Institute of Allergy and Infectious Diseases (NIAID). This clinical trial evaluated whether baricitinib impacted how long it took for subjects who were also taking remdesivir to recover from COVID-19.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.